VIDEO: Current treatment options for ulcerative colitis

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We have several effective therapies now for moderate to severe ulcerative colitis, and these therapies target different players in the inflammatory pathways. We have the biologics, so these are antibodies that target a specific pathway of inflammation: the anti-TNF, the anti-integrin, anti-IL-12/IL-23 and most recently IL-23 inhibitors.

We also have small molecule drugs. They have a chemical structure, but they also target specific pathways of the inflammation, mainly JAK inhibitors and S1PR modulators.

The goals of all these therapies are the same, even though they work mechanistically differently. It’s really to induce and maintain remission, a steroid-free remission; restore the patient quality of life; and prevent disability from having ulcerative colitis.